Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GRP78-PERK pathway is a fundamental branch of the Unfolded Protein Response (UPR) that monitors and responds to endoplasmic reticulum (ER) stress. Under homeostatic conditions, the ER chaperone GRP78 (also known as BiP) remains bound to the luminal domain of the sensor kinase PERK (Eukaryotic translation initiation factor 2-alpha kinase 3), maintaining it in an inactive monomeric state (UniProt: P11021). Upon the accumulation of unfolded proteins, GRP78 dissociates from PERK to assist in protein folding, which triggers PERK dimerization and autophosphorylation. Activated PERK then phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2-alpha), causing a global inhibition of protein translation to reduce the ER workload while selectively promoting the translation of stress-adaptive genes such as ATF4 (UniProt: Q9NZJ5; PubMed: 32051602). This pathway is a major therapeutic target in oncology and neurology. Cancer cells often hijack the GRP78-PERK axis to survive the proteotoxic stress of hypoxic and nutrient-poor microenvironments, making PERK inhibition a strategy to selectively trigger apoptosis in tumors (PubMed: 23676665). Conversely, chronic activation of this pathway in neurodegenerative diseases like Alzheimer's and Parkinson's contributes to synaptic loss through prolonged translation attenuation. Despite its promise, systemic inhibition of PERK poses significant safety challenges, notably pancreatic toxicity and hyperglycemia, as PERK is essential for the health of insulin-secreting beta cells (PubMed: 23056100). Consequently, drug development has expanded to include downstream modulators like the integrated stress response inhibitor ISRIB, which may offer a wider therapeutic window.
Small molecule inhibition of the PERK kinase catalytic domain prevents the phosphorylation of eIF2-alpha, thereby blocking the integrated stress response and sensitizing stressed cells to apoptosis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 2-alpha kinase 3 (PERK) (PERK).